Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE (APPRAISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03608657
Recruitment Status : Recruiting
First Posted : August 1, 2018
Last Update Posted : April 28, 2020
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:

This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study, to initiate treatment with Otezla® will be considered for participation in the study.

Patients will be enrolled from the practices of predominantly community rheumatologists and will be followed for 12 months from the time of initiation of treatment with Otezla® In line with the observational nature of the study, there will be no protocol imposed tests or assessments. However, recommended follow up visits will be at 4, 8 and 12 months. In addition, patients may be asked to voluntarily complete self-administered questionnaires.

The 24-month assessment will be aimed to determine whether or not treatment with Otezla® has been maintained, and if not, to ascertain the reason for discontinuation and what new treatment was initiated following discontinuation of Otezla®


Condition or disease Intervention/treatment
Arthritis, Psoriatic Drug: Apremilast

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study Evaluating the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
Actual Study Start Date : June 15, 2018
Estimated Primary Completion Date : February 21, 2021
Estimated Study Completion Date : February 21, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Apremilast

Group/Cohort Intervention/treatment
Psoriatic Arthritis patients treated with Apremilast
Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
Drug: Apremilast
Apremilast
Other Name: Otezla




Primary Outcome Measures :
  1. The rate of achieving Low Disease Activity (LDA) [ Time Frame: Up to approximately 1 year ]
    Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) < 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).


Secondary Outcome Measures :
  1. The rate of achieving Low Disease Activity (LDA) [ Time Frame: Up to approximately 8 months ]
    Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) < 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).

  2. Tender Joint Count (TJC) [ Time Frame: Up to Approximately 1 year ]
    Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician

  3. Swollen Joint Count (SJC) [ Time Frame: Up to Approximately 1 year ]
    Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician

  4. Assessment of Enthesitis (Leeds Enthesitis Index (LEI) [ Time Frame: Up to Approximately 1 year ]
    This is completed by the treating physician and assesses tenderness at six (6) sites, specifically two (2) lateral at the following: epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. The LEI is scored between 0 and 6. Resolution versus improvement versus no change versus worsening of enthesitis since the last available assessment

  5. Assessment of Dactylitis (Leeds Dactylitis Index) [ Time Frame: Up to approximately 1 year ]
    Resolution versus improvement versus no change versus worsening of dactylitis since the last available assessment

  6. Assessment of Body Surface Area (BSA) [ Time Frame: Up to approximately 1 year ]
    height (cm) x weight (kg)/3600)½

  7. Health Assessment Questionnaire Disability Index (HAQ-DI) [ Time Frame: Up to approximately 1 year ]
    This is a self-administered questionnaire measuring the patient's functional ability during the last week. It consists of 20 items converging to 8 scales measuring dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The patients rate each activity as 0 = without any difficulty, 1 = some difficulty, 2 = much difficulty and 4 = unable. The final score ranges from 0 to 3 with higher scores indicating more disability.

  8. Physician global assessment of disease activity (MDGA) [ Time Frame: Up to approximately 1 year ]
    This is a 100-mm visual analog scale (VAS) with 0 indicating lowest disease and 100 highest disease activities

  9. Patient global assessment of disease activity (PtGA) [ Time Frame: Up to approximately 1 year ]
    This is a 100-mm VAS with 0 indicating lowest disease and 100 highest disease activity

  10. Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: Up to approximately 1 year ]
    This is a 14-item questionnaire evaluating patient satisfaction in terms of the following: effectiveness, side effects, convenience, and global satisfaction

  11. Patient subjective assessment of Pain using a 100mm VAS [ Time Frame: Up to approximately 1 year ]
    Patient subjective assessment of Pain using a 100mm VAS

  12. Psoriatic Arthritis (WPAI:PsA) [ Time Frame: Up to approximately 1 year ]
    A 6-item questionnaire assessing the effect of PsA on the patient's ability to work and perform daily activities. It assesses presenteeism, absenteeism, productivity and activity impairment

  13. Medical Outcomes Study Short- Form 36 (SF-36) [ Time Frame: Up to approximately 1 year ]
    A generic quality of life index that is comprised of 36 items converging to eight (8) domains: Vitality, Physical Functioning, Bodily Pain, General Health Perception, Physical Role Functioning, Emotional Role Functioning, Social Role Functioning, and Mental Health

  14. Patient-reported adherence with PsA treatment from the last visit. [ Time Frame: Up to approximately 1 year ]
    An optional weekly take-home diary will be offered to patients; this diary will aid in documenting how many doses (if any) of PsA treatment were missed, and the reason(s) why.

  15. Proportion of patients in Patient Acceptable Symptom State (PASS) [ Time Frame: Up to approximately 1 year ]
    A single question phrased as "If you were to remain for the next few months as you were during the last week, would this be acceptable or unacceptable to you?" with a binary (Yes or No) response

  16. Adverse Events (AEs) [ Time Frame: From enrollment until at least 28 days after completion of study treatment ]
    Number of subjects with adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients with active PsA and access to commercial Otezla® who are under the care of a Canadian rheumatologist.
Criteria

Inclusion Criteria:

  • Active psoriatic arthritis (PsA) as per the Classification criteria for Psoriatic Arthritis (CASPAR) criteria, based on the investigator's clinical judgement.
  • Adult patients (≥18 years of age) with PsA
  • Prescribing physician has decided to initiate treatment with Otezla®, and this decision was prior to and independent of patient enrollment in the study.
  • Access to commercially available Otezla®

Exclusion Criteria:

  • Patients who are pregnant, breastfeeding, or who are planning on becoming pregnant during the course of the study
  • Participation in Investigational Clinical Trial within the last 60 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03608657


Contacts
Layout table for location contacts
Contact: Amgen Call Center 866-572-6436 medinfo@amgen.com

Locations
Show Show 19 study locations
Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT03608657    
Other Study ID Numbers: CC-10004-PSA-011
U1111-1214-0693 ( Other Identifier: UTN )
First Posted: August 1, 2018    Key Record Dates
Last Update Posted: April 28, 2020
Last Verified: April 2020
Keywords provided by Amgen:
Psoriatic Arthritis
Canada
CC-10004
Apremilast
APPRAISE
Safety
Non-interventional
Observation
DMARDs
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Apremilast
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents